RPG Life Sciences has partnered with Archerchem Healthcare to launch Naprosyn ES in India, a combination medication designed to provide effective anti-inflammatory solutions along with gastro-protection. This strategic collaboration marks the first introduction of a Naproxen and Esomeprazole combination in the Indian market, addressing a significant unmet need for patients requiring long-term Nonsteroidal Anti-Inflammatory Drug (NSAID) therapy. The partnership strengthens the existing business relationship between the two entities, with RPG Life Sciences serving as the exclusive marketing and distribution partner while Archerchem acts as the exclusive supplier.

Partnership Details

Under the agreement, RPG Life Sciences will leverage the strong legacy and brand recall of the Naprosyn brand to drive distribution across the country. The dual-action formulation is designed to provide efficient pain management through Naproxen, a well-established NSAID, while Esomeprazole works to safeguard the gastrointestinal lining. This differentiated formulation is expected to improve patient compliance and enable safer long-term pain management, particularly among elderly and gastro-sensitive populations.

Strategic Impact

Ashok Nair, Managing Director of RPG Life Sciences, stated that the launch exemplifies the company's R&D-driven approach to differentiated products and the trust placed by doctors and patients in the Naprosyn brand. Anil Dhedia, Chairman & Managing Director of Archerchem Healthcare, highlighted the partnership as a demonstration of Archerchem's strength in developing complex differential formulations. The launch aligns with RPG Life Sciences' continued focus on building a differentiated portfolio in chronic therapy segments, utilizing its robust reach to a wide spectrum of doctors and pan-India distribution network.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE105J01010/5615a4bb-1d1c-497d-937c-dc856287e98c.pdf

RPG Life Sciences Limited has announced the schedule for its Nineteenth Annual General Meeting (AGM), scheduled for Thursday, July 23, 2026, at 3.00 p.m. IST via Video Conferencing. The company has fixed Thursday, July 16, 2026, as the record date to determine the eligibility of members entitled to receive the dividend, subject to shareholder approval. The remote e-voting facility will be available from Monday, July 20, 2026, at 09:00 a.m. to Wednesday, July 22, 2026, at 05:00 p.m.

Financial Performance

The company reported total income of ₹733.06 crores for the year ended March 31, 2026, compared to ₹666.11 crores in the previous year. Revenue from operations stood at ₹707.52 crores, registering a growth of 8.3%. Profit for the year after tax was ₹115.17 crores, while EBITDA margins were maintained at 24.4%. The balance sheet remained strong with cash reserves of approximately ₹275 crores.

Segment and Operational Highlights

Domestic Formulations revenue grew 13.8% year-on-year to ₹483.5 crores, outperforming the Indian Pharmaceutical Market growth of 8.6%. International Formulations reported a de-growth of 6.7% to ₹123.43 crores, while API sales increased 5.3% to ₹95.06 crores. The API plant is now fully operational following restoration post the fire incident. The Board has recommended a final dividend of ₹24 per equity share (300%) for FY 2025-26.